China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Employees

142

Sector

Healthcare Facilities & Services

Calendar

28/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
19/08/26	HKD 0.6150	-0.81%	90,000
18/08/26	HKD 0.6200	-0.80%	80,000
17/08/26	HKD 0.6250	-0.79%	70,000
14/08/26	HKD 0.6300	-1.56%	335,000
13/08/26	HKD 0.6400	-1.54%	360,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. 06:08:48 19/08/26 pm AEST			5-day change	1st Jan Change
0.6150 ^HKD	-0.81%		-3.91%	-22.15%

13/08	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
12/08	China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug	CI

Market Cap	600M 76.53M 65.65M 61.3M 56.24M 106M 7.32B 108M 723M 283M 3.67B 287M 281M 12.13B	P/E 2024	-2.49x	P/E 2025	-11.2x
Enterprise Value	983M 125M 108M 100M 92.12M 173M 11.98B 176M 1.18B 464M 6.01B 471M 460M 19.87B	EV / Sales 2024	9.45x	EV / Sales 2025	15.7x
Free-Float	35.46%	Yield 2024 *	-	Yield 2025	-

13/08	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
12/08	China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug	CI
03/08	China Biotech Services Holdings Limited's Japan, Pengbo Medical Technology Co., Ltd. Present of Initial Follow-Up Findings of Boron Neutron Capture Therapy At the 22Nd Congress on Neutron Capture Therapy	CI
19/05	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
01/05	China Biotech Services says He Xun resigns as executive director	RE
30/04	China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026	CI
29/04	China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
28/03	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
07/03	China Biotech Services expects FY net loss of not more than HK$100 million	RE
06/03	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025	CI
20/02	China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd	CI
30/12	China Biotech Services to issue convertible bonds	RE
29/12	China Biotech Services Holdings Limited announced that it expects to receive HKD 272.3 million in funding	CI

10/01/23	China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate	AQ
24/06/22	Sumitomo Heavy Industries, Ltd. - Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China	AQ
10/08/21	China Biotech Services : AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China	AQ
28/06/21	China Biotech Services (8037.HK): Confident shareholders are taking long on their books in anticipation of promising results to be generated from the double engines of growth on cell therapy and precision diagnostic businesses	AQ
29/01/21	China Biotech Services : Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40	AQ

China Biotech Services Holdings Limited Stock

Stocks

8037

BMG2152F1014

Healthcare Facilities & Services

Valuation: China Biotech Services Holdings Limited

Chart: China Biotech Services Holdings Limited

Latest news : China Biotech Services Holdings Limited

Press Releases: China Biotech Services Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: China Biotech Services Holdings Limited

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-0.81%
1 week	-3.91%
Current month	-0.81%
1 month	-5.38%
3 months	+2.50%
6 months	-20.13%
Current year	-22.15%

1 week	0.6	0.67
1 month	0.58	0.7
Current year	0.3	0.92
1 year	0.3	1.33
3 years	0.25	1.33
5 years	0.25	2.64
10 years	0.16	2.64

Manager	Title	Age	Since
Eddy Lai DFI	Director of Finance/CFO	-	-
Xiao Lin Liu CMP	Compliance Officer	55	26/05/2022
Xuan ming Yang CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Guo Xiang Yan BRD	Director/Board Member	60	07/08/2017
Song Huang BRD	Director/Board Member	44	15/09/2017
Xiao Lin Liu CHM	Chairman	55	28/08/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/9/24	Xun He	Other	Director	3,220,000	0.3300%
13/6/24	Hoi Yam Chui	Other	Director	5,000,000	0.5191%
19/1/24	Xiao Lin Liu	Other	Chairman	30,000	0.0031%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA BIOTECH SERVICES HOLDINGS LIMITED	-0.81%	-3.91%	-30.11%	-5.38%	77.12M
CVS HEALTH CORPORATION	-1.35%	-1.45%	+31.53%	+39.15%	121B
HCA HEALTHCARE, INC.	+0.53%	-0.18%	+2.77%	+50.58%	89.14B
QUEST DIAGNOSTICS INCORPORATED	+1.78%	+0.97%	+31.31%	+80.66%	26.08B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.89%	+2.49%	-5.85%	-8.31%	22.03B
TENET HEALTHCARE CORPORATION	+0.85%	+2.20%	+53.16%	+280.66%	21.76B
REDE D'OR SÃO LUIZ S.A.	+2.29%	+3.26%	-10.10%	+11.91%	13.72B
FRESENIUS MEDICAL CARE AG	+0.52%	-0.20%	-4.84%	-7.13%	12.5B
DAVITA INC.	+0.33%	-2.00%	+30.14%	+74.57%	11.35B
PT SEJAHTERARAYA ANUGRAHJAYA TBK	-0.83%	+14.42%	+150.00%	+2,153.79%	10.28B
Average	+0.41%	+1.41%	+24.80%	+267.05%	32.83B
Weighted average by Cap.	+0.00%	+1.21%	+23.15%	+122.90%

	2024	2025
Net sales	70.51M 8.99M 7.71M 7.2M 6.61M 12.43M 860M 12.63M 84.99M 33.28M 431M 33.77M 33.03M 1.43B	73.5M 9.37M 8.04M 7.51M 6.89M 12.96M 896M 13.17M 88.6M 34.69M 449M 35.2M 34.43M 1.49B
Net income	-198M -25.27M -21.68M -20.24M -18.57M -34.92M -2.42B -35.5M -239M -93.53M -1.21B -94.89M -92.82M -4.01B	-68.78M -8.77M -7.52M -7.03M -6.45M -12.12M -838M -12.32M -82.91M -32.46M -420M -32.94M -32.22M -1.39B
Net Debt	169M 21.54M 18.48M 17.26M 15.83M 29.77M 2.06B 30.26M 204M 79.73M 1.03B 80.89M 79.13M 3.41B	383M 48.82M 41.88M 39.11M 35.88M 67.47M 4.67B 68.58M 461M 181M 2.34B 183M 179M 7.74B